Abuse potential and pharmacodynamic characteristics of oral and intranasal eluxadoline, a mixed μ- And κ-opioid receptor agonist and δ-opioid receptor antagonist

Journal of Pharmacology and Experimental Therapeutics

Volumn 359, Issue 3, 2016, Pages 471-481

  Levy Cooperman, N ^a   McIntyre, G ^b   Bonifacio, L ^c   McDonnell, M ^d   Davenport, J M ^e   Covington, P S ^e   Dove, L S ^e   Sellers, E M ^f  

^a Altreos Research Partners   (Canada)

^b IntelliDev Consulting   (United States)

^c Lodestar Pharma Consulting LLC   (United States)

^d SYNEOS HEALTH   (United States)

^e ALLERGAN PLC   (United States)

^f UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DELTA OPIATE RECEPTOR ANTAGONIST; ELUXADOLINE; KAPPA OPIATE RECEPTOR AGONIST; MU OPIATE RECEPTOR AGONIST; NALOXONE; OXYCODONE; PLACEBO; DELTA OPIATE RECEPTOR; IMIDAZOLE DERIVATIVE; KAPPA OPIATE RECEPTOR; MU OPIATE RECEPTOR; PHENYLALANINE;

ADULT; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG ABUSE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFECT; DRUG TOLERABILITY; DRUG WITHDRAWAL; EUPHORIA; FACE PAIN; FATIGUE; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM DRUG EFFECT; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; NOSE IRRITATION; NOSE OBSTRUCTION; PHARMACODYNAMICS; PRIORITY JOURNAL; PROVOCATION TEST; PUPILLOMETRY; RANDOMIZED CONTROLLED TRIAL; RHINORRHEA; RISK FACTOR; SIDE EFFECT; SOMNOLENCE; TIME TO MAXIMUM PLASMA CONCENTRATION; VISUAL ANALOG SCALE; VOMITING; AGONISTS; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; INTRANASAL DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PSYCHOLOGY; PSYCHOMETRY; SUBSTANCE-RELATED DISORDERS;

ADMINISTRATION, INTRANASAL; ADMINISTRATION, ORAL; ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMIDAZOLES; MALE; PHENYLALANINE; PSYCHOMETRICS; RECEPTORS, OPIOID, DELTA; RECEPTORS, OPIOID, KAPPA; RECEPTORS, OPIOID, MU; SUBSTANCE-RELATED DISORDERS;

EID: 84994744769     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.116.236547     Document Type: Article

References (25)

1. Abdelhamid EE, Sultana M, Portoghese PS, and Takemori AE (1991) Selective blockage of delta opioid receptors prevents the development of morphine tolerance and dependence in mice. J Pharmacol Exp Ther 258:299-303.
2. Abreu ME, Bigelow GE, Fleisher L, and Walsh SL (2001) Effect of intravenous injection speed on responses to cocaine and hydromorphone in humans. Psychopharmacology (Berl) 154:76-84.
3. Chavkin C (2011) The therapeutic potential of k-opioids for treatment of pain and addiction. Neuropsychopharmacology 36:369-370.
4. Davenport JM, Covington P, Bonifacio L, McIntyre G, and Venitz J (2015) Effect of uptake transporters OAT3 and OATP1B1 and efflux transporter MRP2 on the pharmacokinetics of eluxadoline. J Clin Pharmacol 55:534-542.
5. Fujita W, Gomes I, Dove LS, Prohaska D, McIntyre G, and Devi LA (2014) Molecular characterization of eluxadoline as a potential ligand targeting mu-delta opioid receptor heteromers. Biochem Pharmacol 92:448-456.
6. Jaffe JH, Kanzler M, and Green J (1980) Abuse potential of loperamide. Clin Pharmacol Ther 28:812-819.
7. Lamb RJ and Griffiths RR (1990) Self-administration in baboons and the discriminative stimulus effects in rats of bupropion, nomifensine, diclofensine and imipramine. Psychopharmacology (Berl) 102:183-190.
8. Lembo AJ, Lacy BE, Zuckerman MJ, Schey R, Dove LS, Andrae DA, Davenport JM, McIntyre G, Lopez R, Turner L, et al. (2016) Eluxadoline for irritable bowel syndrome with diarrhea. N Engl J Med 374:242-253.
9. Perrino PJ, Colucci S, Harris S, and Sellers E (2012) Evaluation of abuse potential of crushed and intranasally administered oxycodone tablets. 74th Annual College on Problems of Drug Dependence Annual Meeting; 2012 June 9-14; Palm Springs, California. College on Problems of Drug Dependence Annual Meeting, Philadelphia, PA.
10. Preston KL and Bigelow GE (2000) Effects of agonist-antagonist opioids in humans trained in a hydromorphone/not hydromorphone discrimination. J Pharmacol Exp Ther 295:114-124.
11. Samaha AN, Mallet N, Ferguson SM, Gonon F, and Robinson TE (2004) The rate of cocaine administration alters gene regulation and behavioral plasticity: implications for addiction. J Neurosci 24:6362-6370.
12. Schiller PW, Weltrowska G, Berezowska I, Nguyen TM, Wilkes BC, Lemieux C, and Chung NN (1999) The TIPP opioid peptide family: development of delta antagonists, delta agonists, and mixed mu agonist/delta antagonists. Biopolymers 51: 411-425.
13. Schlaepfer TE, Strain EC, Greenberg BD, Preston KL, Lancaster E, Bigelow GE, Barta PE, and Pearlson GD (1998) Site of opioid action in the human brain: mu and kappa agonists' subjective and cerebral blood flow effects. Am J Psychiatry 155: 470-473.
14. Sellers EM and Spivey (2009) Re-evaluation of the pharmacodynamics, pharmacokinetics, safety and tolerability of Acurox® tablets compared with oxycodone HCl tablets and oxycodone HCl powder administered intranasally to recreational opioid abusers. 25th Annual Meeting of the American Academy of Pain Management; 2009 Jan 28-31; Honolulu, HI. American Academy of Pain Management, Chicago, IL.
15. Stoops WW, Hatton KW, Lofwall MR, Nuzzo PA, and Walsh SL (2010) Intravenous oxycodone, hydrocodone, and morphine in recreational opioid users: abuse potential and relative potencies. Psychopharmacology (Berl) 212:193-203.
16. Tella SR, Ladenheim B, and Cadet JL (1997) Differential regulation of dopamine transporter after chronic self-administration of bupropion and nomifensine. J Pharmacol Exp Ther 281:508-513.
17. US DEA (Drug Enforcement Administration) (2015a) Schedules of Controlled Substances: Placement of Eluxadoline Into Schedule IV. Final rule. Fed Regist 80: 69861-69864.
18. US DEA (Drug Enforcement Administration) (2015b) Schedules of Controlled Substances: Placement of Eluxadoline into Schedule IV. Notice of proposed rulemaking. Fed Regist 80:48044-48051.
19. Wade PR, Palmer JM, McKenney S, Kenigs V, Chevalier K, Moore BA, Mabus JR, Saunders PR, Wallace NH, Schneider CR, et al. (2012) Modulation of gastrointestinal function by MuDelta, a mixed m opioid receptor agonist/m opioid receptor antagonist. Br J Pharmacol 167:1111-1125.
20. Walsh SL, Nuzzo PA, Lofwall MR, and Holtman JR, Jr (2008) The relative abuse liability of oral oxycodone, hydrocodone and hydromorphone assessed in prescription opioid abusers. Drug Alcohol Depend 98:191-202.
21. Walsh SL, Strain EC, Abreu ME, and Bigelow GE (2001) Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans. Psychopharmacology (Berl) 157:151-162.
22. Wightman R, Perrone J, Portelli I, and Nelson L (2012) Likeability and abuse liability of commonly prescribed opioids. J Med Toxicol 8:335-340.
23. Yanagita T, Miyasato K, and Sato J (1979) Dependence potential of loperamide studied in rhesus monkeys. NIDA Res Monogr 27:106-113.
24. Zacny JP, Hill JL, Black ML, and Sadeghi P (1998) Comparing the subjective, psychomotor and physiological effects of intravenous pentazocine and morphine in normal volunteers. J Pharmacol Exp Ther 286:1197-1207.
25. Zacny JP and Lichtor SA (2008) Within-subject comparison of the psychopharmacological profiles of oral oxycodone and oral morphine in non-drug-abusing volunteers. Psychopharmacology (Berl) 196:105-116.